Case report: Prolonged and severe hungry bone syndrome after parathyroidectomy in X-linked hypophosphatemia.

IF 3.9 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Frontiers in Endocrinology Pub Date : 2025-01-07 eCollection Date: 2024-01-01 DOI:10.3389/fendo.2024.1496386
Giulia Puliani, Valeria Hasenmajer, Matteo Spaziani, Federico Frusone, Chiara Tarantino, Francesco Angelini, Ludovica Vincenzi, Riccardo Lubrano, Alessia Marcellino, Marco Biffoni, Andrea M Isidori
{"title":"Case report: Prolonged and severe hungry bone syndrome after parathyroidectomy in X-linked hypophosphatemia.","authors":"Giulia Puliani, Valeria Hasenmajer, Matteo Spaziani, Federico Frusone, Chiara Tarantino, Francesco Angelini, Ludovica Vincenzi, Riccardo Lubrano, Alessia Marcellino, Marco Biffoni, Andrea M Isidori","doi":"10.3389/fendo.2024.1496386","DOIUrl":null,"url":null,"abstract":"<p><p>Tertiary hyperparathyroidism is characterized by hypercalcemia resulting from autonomous parathyroid hormone production and usually occurs after a prolonged period of secondary hyperparathyroidism. This condition can be a complication of X-linked hypophosphatemia (XLH), a rare genetic disease characterized by renal phosphate loss and consequent hypophosphatemia. Parathyroidectomy is considered the first-line therapy but surgical intervention can be complicated by hungry bone syndrome. A male Caucasian patient presented with XLH, diagnosed at the age of 3 years. At the age of 21, tertiary hyperparathyroidism occurred. Neck ultrasonography, neck magnetic resonance imaging, and <sup>99</sup>Tc-sestamibi parathyroid scintigraphy revealed two hyperplastic parathyroid glands. To minimize the risk of hypercalcemia, calcimimetic therapy was initiated. After 6 months and preparation with 1,25-dihydroxy vitamin D, the patient underwent total parathyroidectomy with autotransplantation of half of a parathyroid gland into the sternocleidomastoid muscle. Histopathological examination revealed diffuse microscopical hyperplasia of the parathyroid glands. Despite oral supplementation with calcium carbonate and calcitriol, severe hypocalcemia developed on the second postoperative day, attributable to hungry bone syndrome. This finding was confirmed by an increase in bone turnover markers and a reduction in urinary calcium excretion. Hypocalcemia correction required continuous infusion of calcium gluconate for over 2 months. After approval, the patient began burosumab therapy with significant benefits. This case illustrates the complexity of treating tertiary hyperparathyroidism and mineral metabolism in patients with XLH. The hungry bone syndrome can complicate parathyroidectomy, exposing the patients to life-threatening risks. Burosumab therapy may reduce the risk of tertiary hyperparathyroidism developing in these patients.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"15 ","pages":"1496386"},"PeriodicalIF":3.9000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11746029/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fendo.2024.1496386","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Tertiary hyperparathyroidism is characterized by hypercalcemia resulting from autonomous parathyroid hormone production and usually occurs after a prolonged period of secondary hyperparathyroidism. This condition can be a complication of X-linked hypophosphatemia (XLH), a rare genetic disease characterized by renal phosphate loss and consequent hypophosphatemia. Parathyroidectomy is considered the first-line therapy but surgical intervention can be complicated by hungry bone syndrome. A male Caucasian patient presented with XLH, diagnosed at the age of 3 years. At the age of 21, tertiary hyperparathyroidism occurred. Neck ultrasonography, neck magnetic resonance imaging, and 99Tc-sestamibi parathyroid scintigraphy revealed two hyperplastic parathyroid glands. To minimize the risk of hypercalcemia, calcimimetic therapy was initiated. After 6 months and preparation with 1,25-dihydroxy vitamin D, the patient underwent total parathyroidectomy with autotransplantation of half of a parathyroid gland into the sternocleidomastoid muscle. Histopathological examination revealed diffuse microscopical hyperplasia of the parathyroid glands. Despite oral supplementation with calcium carbonate and calcitriol, severe hypocalcemia developed on the second postoperative day, attributable to hungry bone syndrome. This finding was confirmed by an increase in bone turnover markers and a reduction in urinary calcium excretion. Hypocalcemia correction required continuous infusion of calcium gluconate for over 2 months. After approval, the patient began burosumab therapy with significant benefits. This case illustrates the complexity of treating tertiary hyperparathyroidism and mineral metabolism in patients with XLH. The hungry bone syndrome can complicate parathyroidectomy, exposing the patients to life-threatening risks. Burosumab therapy may reduce the risk of tertiary hyperparathyroidism developing in these patients.

病例报告:x连锁低磷血症患者甲状旁腺切除术后长期和严重的饥饿骨综合征。
三期甲状旁腺功能亢进的特点是由甲状旁腺激素分泌引起的高钙血症,通常发生在继发性甲状旁腺功能亢进长期后。这种情况可能是x连锁低磷血症(XLH)的并发症,XLH是一种罕见的遗传性疾病,以肾磷酸盐丢失和随之而来的低磷血症为特征。甲状旁腺切除术被认为是一线治疗方法,但手术干预可能会因饥饿骨综合征而复杂化。一名男性白种人患者在3岁时被诊断为XLH。在21岁时,发生了三级甲状旁腺功能亢进。颈部超声、颈部磁共振及99Tc-sestamibi甲状旁腺显像示2个甲状旁腺增生。为了降低高钙血症的风险,开始了拟钙化治疗。在接受1,25-二羟基维生素D治疗6个月后,患者接受了全甲状旁腺切除术,并将一半甲状旁腺自体移植到胸锁乳突肌中。组织病理学检查显示甲状旁腺弥漫性显微镜下增生。尽管口服补充碳酸钙和骨化三醇,术后第二天发生严重的低钙血症,可归因于饥饿骨综合征。这一发现被骨转换标志物的增加和尿钙排泄的减少所证实。低钙矫正需要持续输注葡萄糖酸钙2个月以上。获得批准后,患者开始接受布罗单抗治疗,获益显著。这个病例说明了治疗XLH患者的三级甲状旁腺功能亢进和矿物质代谢的复杂性。饥饿骨综合征会使甲状旁腺切除术复杂化,使患者面临生命危险。布若单抗治疗可降低这些患者发生三级甲状旁腺功能亢进的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Endocrinology
Frontiers in Endocrinology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
5.70
自引率
9.60%
发文量
3023
审稿时长
14 weeks
期刊介绍: Frontiers in Endocrinology is a field journal of the "Frontiers in" journal series. In today’s world, endocrinology is becoming increasingly important as it underlies many of the challenges societies face - from obesity and diabetes to reproduction, population control and aging. Endocrinology covers a broad field from basic molecular and cellular communication through to clinical care and some of the most crucial public health issues. The journal, thus, welcomes outstanding contributions in any domain of endocrinology. Frontiers in Endocrinology publishes articles on the most outstanding discoveries across a wide research spectrum of Endocrinology. The mission of Frontiers in Endocrinology is to bring all relevant Endocrinology areas together on a single platform.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信